Xtrana to develop nucleic acid-based chlamydia test:
This article was originally published in Clinica
US company Xtrana is to develop a nucleic acid-based test for Chlamydia trachomatis using a Phase I grant from the US National Institutes of Health. The test, for use in the doctor's office or at a healthcare clinic, uses an isothermal method for amplification, eliminating the need for expensive and complex equipment such as thermocyclers, said the Denver, Colorado-based company. Xtrana added that the new test detected RNA from chlamydia and would therefore be more specific to live organisms than DNA-based tests or antibody/antigen tests.